I've watched three PE deals die in the last six months. Not because of valuation disputes or market timing, but because buyers couldn't verify that the revenue would survive ownership transition.
The Bain/StepStone survey confirms what I'm seeing: poor earnings quality and customer churn now kill more deals than inflated seller expectations. But the survey doesn't capture the real problem — most portfolio companies can't answer basic questions about revenue durability.
The Questions That Kill Deals
When I work with PE-backed companies preparing for exit, the same questions surface in every diligence process:
- Will this revenue survive if the founder steps back?
- Can we predict customer behavior 12 months out?
- Is the pricing defensible or just what the market accepted?
- What happens to expansion revenue when competitors catch up?
Most companies can't answer these questions because their sales process lives in individual relationships, not repeatable systems.
What I've Learned From Failed Diligence
The companies that pass revenue quality tests share five characteristics:
Their sales process survives personnel changes. Customer acquisition isn't dependent on founder relationships or individual rep performance.
Their forecasts actually predict reality. Pipeline numbers consistently hit within 10-15% of projections.
They can defend their pricing. There's documented evidence that customers pay for specific value, not just market positioning.
Their competitive position is research-backed. They know exactly why customers choose them over alternatives, based on actual customer interviews.
Their data tells a coherent story. Revenue decisions are supported by comparable metrics that make sense to institutional buyers.
The Hard Truth About Revenue Operations
Most portfolio companies treat revenue operations like a collection of tools rather than a system. CRM data that doesn't connect to customer research. Pipeline forecasts based on rep intuition. Competitive positioning that sounds good in pitch decks but crumbles under buyer scrutiny.
This works fine for growth-stage companies with patient capital. It fails catastrophically in PE diligence.
What This Means for Your Portfolio
If you're preparing companies for exit, start with revenue diagnostics 18-24 months before market timing. The companies that survive diligence have systematic answers to systematic questions.
The ones that don't... well, that's how deals die in 2026.